Up next

Autoplay

EXPLORER: Avapritinib in systemic mastocytosis

1 Views • 07/09/23
Share
Embed
administrator
administrator
Subscribers
0

Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, presents findings from a mutational analysis of the Phase 1 EXPLORER trial (NCT02561988), which assessed avapritinib in patients with advanced systemic mastocytosis (AdvSM) and an associated hematologic neoplasm (AHN), primarily driven by KIT D816V mutations. Treatment with avapritinib in patients reported superior survival outcomes and significantly reduced KIT D816V disease burden in the majority of patients. Re-emergence of the mutations was additionally rarely seen in the patient cohort. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay